BIOPOR Bioporto A/S

Grant of warrants

Grant of warrants

May 11, 2020

Announcement no. 14





Grant of warrants

Today, the Board of Directors of BioPorto A/S ("BioPorto") (Nasdaq: BIOPOR) has exercised part of its current authorization by issuing 2,150,000 warrants to its US Corporate Management and certain of the company’s key employees.

The warrants are issued in accordance with the company's Remuneration policy, its guidelines for incentive-based remuneration and the authorization in section 18 of the Articles of Association.

Each warrant grants the holder the right to subscribe for one share in the Company. The exercise price is fixed at DKK 2.72 per share corresponding to the last 10 days volume weighted average price of BioPorto’s stock traded on Nasdaq Copenhagen A/S. The warrants will be exercisable in the period from May 11, 2022 – May 10, 2025. Within the exercise period, warrants can be exercised within ordinary trading windows.

The program includes conditions on claw-back in case of erroneous financial information and on accelerated vesting in case of change of control, e.g. a takeover bid, resolution and business transfer.

The theoretical market value of the allocations of warrants amounts to DKK 2,005,031. The calculation is based on the Black-Scholes formula using an interest rate of -0.60% and the historical volatility of BioPorto A/S' shares over 24 months, calculated to be 63.45.

The detailed terms of all warrants issued by the Company can be found in the Articles of Association on under Investor Relations> Governance> Company Articles.

After this grant of warrants the total number of outstanding warrants is 18,682,500 as shown in the table below:

 Number of warrants: Specified as follows:
Warrant programsGrantedCancelledOutstanding Corporate ManagementOther employeesTotal
        
20166,368,696 3,936,196 2,432,500  910,000 1,522,500 2,432,500
 Jun 2018900,000 0 900,000  900,000 0 900,000
 Aug 20184,100,000 0 4,100,000  3,700,000 400,000 4,100,000
 Dec 20182,500,000 0 2,500,000  2,500,000 0 2,500,000
Apr 20195,100,000 0 5,100,000  5,100,000 0 5,100,000
Aug 20191,500,000 250,000 1,250,000  1,000,000 250,000 1,250,000
Dec 2019250,000 0 250,000  0 250,000 250,000
May 20202,150,000 0 2,150,000  1,500,000 650,000 2,150,000
Total22,868,696 4,186,196 18,682,500  15,610,000 3,072,500 18,682,500

For further information, please contact:

Thomas Magnussen, Chairman of the Board

Ole Larsen, CFO

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

 

Attachment

EN
11/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE

BioPorto sponsorerer konferencer om pædiatrisk intensiv behandling med...

BioPorto sponsorerer konferencer om pædiatrisk intensiv behandling med præsentation af nye videnskabelige data om NGAL 26. september, 2025Meddelelse BioPorto sponsorerer konferencer om pædiatrisk intensiv behandling med præsentation af nye videnskabelige data om NGAL KØBENHAVN, DANMARK og BOSTON, MA, USA, 26. september – BioPorto A/S (“BioPorto” eller “Selskabet”) (CPH:BIOPOR), annoncerer sin støtte til konferencer med fokus på pædiatriske organtransplantationer og intensiv behandling indenfor nefrologi. Kliniske forskere præsenterer posters, resuméer og nye publikationer, hvor NGAL anven...

 PRESS RELEASE

BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL...

BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented September 26, 2025News Release BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented COPENHAGEN, DENMARK and BOSTON, MA, USA, September 26 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), is pleased to support conferences focused on pediatric solid organ transplants and critical care nephrology. Clinical researchers present posters, abstracts and new publications using NGAL in their patients, leading to better identification for risk of Acut...

 PRESS RELEASE

US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæ...

US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæver NGAL-biomarkøren 11. september, 2025Meddelelse US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæver NGAL-biomarkøren KØBENHAVN, DANMARK og BOSTON, MA, USA, 11. september – BioPorto A/S (BioPorto eller Selskabet) (CPH:BIOPOR) annoncerer det kommende virtuelle arrangement fra US News & World Report: “New Frontiers in Kidney Care”, som vil fokusere på akut og kronisk nyresygdom globalt samt de tiltag, der kan sikre de bedst mulige behandlingsresultater inden for nyresundhed. Webinaret afholdes tors...

 PRESS RELEASE

US News & World Report Webinar “New Frontiers in Kidney Care” features...

US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker September 11, 2025News Release US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker COPENHAGEN, DENMARK and BOSTON, MA, USA, September 11 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), is pleased to announce the upcoming US News & World Report live virtual event "New Frontiers in Kidney Care” which will focus on acute and chronic kidney disease globally and actions that can be taken to ensure best possible outcomes in kidney care. The program will run live on ...

 PRESS RELEASE

Tildeling af Warrants

Tildeling af Warrants 1. september 2025 Meddelelse nr. 20                                                                          Tildeling af Warrants København, Danmark, den 1. september 2025 (GLOBE NEWSWIRE) – Bestyrelsen for BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) har i dag besluttet at udstede i alt 5.000.000 warrants til et medlem af Selskabets direktion. Hver warrant giver indehaveren ret til at tegne én aktie i BioPorto til en udnyttelseskurs på 1,28 kr. pr. aktie, svarende til lukkekursen på Nasdaq Copenhagen i dag. Warrants udstedes i henhold til § 18 a i S...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch